Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Ligandomes obtained from different HLA-class II-molecules are homologous for N- and C-terminal residues outside the peptide-binding cleft.

Kampstra ASB, van Heemst J, Janssen GM, de Ru AH, van Lummel M, van Veelen PA, Toes REM.

Immunogenetics. 2019 Sep;71(8-9):519-530. doi: 10.1007/s00251-019-01129-6. Epub 2019 Sep 13.

PMID:
31520135
2.

Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.

van der Lee DI, Reijmers RM, Honders MW, Hagedoorn RS, de Jong RC, Kester MG, van der Steen DM, de Ru AH, Kweekel C, Bijen HM, Jedema I, Veelken H, van Veelen PA, Heemskerk MH, Falkenburg JHF, Griffioen M.

J Clin Invest. 2019 Feb 1;129(2):774-785. doi: 10.1172/JCI97482. Epub 2019 Jan 14.

3.

Epitope Stealing as a Mechanism of Dominant Protection by HLA-DQ6 in Type 1 Diabetes.

van Lummel M, Buis DTP, Ringeling C, de Ru AH, Pool J, Papadopoulos GK, van Veelen PA, Reijonen H, Drijfhout JW, Roep BO.

Diabetes. 2019 Apr;68(4):787-795. doi: 10.2337/db18-0501. Epub 2019 Jan 9.

4.

Glycoproteomic Analysis of MGL-Binding Proteins on Acute T-Cell Leukemia Cells.

Pirro M, Schoof E, van Vliet SJ, Rombouts Y, Stella A, de Ru A, Mohammed Y, Wuhrer M, van Veelen PA, Hensbergen PJ.

J Proteome Res. 2019 Mar 1;18(3):1125-1132. doi: 10.1021/acs.jproteome.8b00796. Epub 2019 Jan 9.

5.

Molecular Pathways for Immune Recognition of Preproinsulin Signal Peptide in Type 1 Diabetes.

Kronenberg-Versteeg D, Eichmann M, Russell MA, de Ru A, Hehn B, Yusuf N, van Veelen PA, Richardson SJ, Morgan NG, Lemberg MK, Peakman M.

Diabetes. 2018 Apr;67(4):687-696. doi: 10.2337/db17-0021. Epub 2018 Jan 17.

6.

Specific T Cell Responses against Minor Histocompatibility Antigens Cannot Generally Be Explained by Absence of Their Allelic Counterparts on the Cell Surface.

Bijen HM, Hassan C, Kester MGD, Janssen GMC, Hombrink P, de Ru AH, Drijfhout JW, Meiring HD, de Jong AP, Falkenburg JHF, Jimenez CR, Heemskerk MHM, van Veelen PA.

Proteomics. 2018 Jun;18(12):e1700250. doi: 10.1002/pmic.201700250. Epub 2018 Feb 23.

PMID:
29251415
7.

Pitfalls in the detection of citrullination and carbamylation.

Verheul MK, van Veelen PA, van Delft MAM, de Ru A, Janssen GMC, Rispens T, Toes REM, Trouw LA.

Autoimmun Rev. 2018 Feb;17(2):136-141. doi: 10.1016/j.autrev.2017.11.017. Epub 2017 Dec 2. Review.

8.

A Specialist Macaque MHC Class I Molecule with HLA-B*27-like Peptide-Binding Characteristics.

de Groot NG, Heijmans CMC, de Ru AH, Janssen GMC, Drijfhout JW, Otting N, Vangenot C, Doxiadis GGM, Koning F, van Veelen PA, Bontrop RE.

J Immunol. 2017 Nov 15;199(10):3679-3690. doi: 10.4049/jimmunol.1700502. Epub 2017 Oct 11.

9.

Breach of autoreactive B cell tolerance by post-translationally modified proteins.

Dekkers JS, Verheul MK, Stoop JN, Liu B, Ioan-Facsinay A, van Veelen PA, de Ru AH, Janssen GMC, Hegen M, Rapecki S, Huizinga TWJ, Trouw LA, Toes REM.

Ann Rheum Dis. 2017 Aug;76(8):1449-1457. doi: 10.1136/annrheumdis-2016-210772. Epub 2017 Apr 25.

PMID:
28442530
10.

TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.

Jahn L, Hombrink P, Hagedoorn RS, Kester MG, van der Steen DM, Rodriguez T, Pentcheva-Hoang T, de Ru AH, Schoonakker MP, Meeuwsen MH, Griffioen M, van Veelen PA, Falkenburg JH, Heemskerk MH.

Blood. 2017 Mar 9;129(10):1284-1295. doi: 10.1182/blood-2016-09-737536. Epub 2017 Jan 4.

PMID:
28053195
11.

CD4 T-cell cytokines synergize to induce proliferation of malignant and nonmalignant innate intraepithelial lymphocytes.

Kooy-Winkelaar YM, Bouwer D, Janssen GM, Thompson A, Brugman MH, Schmitz F, de Ru AH, van Gils T, Bouma G, van Rood JJ, van Veelen PA, Mearin ML, Mulder CJ, Koning F, van Bergen J.

Proc Natl Acad Sci U S A. 2017 Feb 7;114(6):E980-E989. doi: 10.1073/pnas.1620036114. Epub 2017 Jan 3.

12.

Parallel reaction monitoring of clinical Mycobacterium tuberculosis lineages reveals pre-existent markers of rifampicin tolerance in the emerging Beijing lineage.

de Keijzer J, Mulder A, de Ru AH, van Soolingen D, van Veelen PA.

J Proteomics. 2017 Jan 6;150:9-17. doi: 10.1016/j.jprot.2016.08.022. Epub 2016 Aug 26.

PMID:
27576137
13.

Multimodal Mass Spectrometry Imaging of N-Glycans and Proteins from the Same Tissue Section.

Heijs B, Holst S, Briaire-de Bruijn IH, van Pelt GW, de Ru AH, van Veelen PA, Drake RR, Mehta AS, Mesker WE, Tollenaar RA, Bovée JV, Wuhrer M, McDonnell LA.

Anal Chem. 2016 Aug 2;88(15):7745-53. doi: 10.1021/acs.analchem.6b01739. Epub 2016 Jul 14.

PMID:
27373711
14.

Thioridazine Alters the Cell-Envelope Permeability of Mycobacterium tuberculosis.

de Keijzer J, Mulder A, de Haas PE, de Ru AH, Heerkens EM, Amaral L, van Soolingen D, van Veelen PA.

J Proteome Res. 2016 Jun 3;15(6):1776-86. doi: 10.1021/acs.jproteome.5b01037. Epub 2016 May 9.

PMID:
27068340
15.

Dendritic Cells Guide Islet Autoimmunity through a Restricted and Uniquely Processed Peptidome Presented by High-Risk HLA-DR.

van Lummel M, van Veelen PA, de Ru AH, Janssen GM, Pool J, Laban S, Joosten AM, Nikolic T, Drijfhout JW, Mearin ML, Aanstoot HJ, Peakman M, Roep BO.

J Immunol. 2016 Apr 15;196(8):3253-63. doi: 10.4049/jimmunol.1501282. Epub 2016 Mar 4.

16.

Mechanisms of Phenotypic Rifampicin Tolerance in Mycobacterium tuberculosis Beijing Genotype Strain B0/W148 Revealed by Proteomics.

de Keijzer J, Mulder A, de Beer J, de Ru AH, van Veelen PA, van Soolingen D.

J Proteome Res. 2016 Apr 1;15(4):1194-204. doi: 10.1021/acs.jproteome.5b01073. Epub 2016 Mar 24.

PMID:
26930559
17.

Human islets and dendritic cells generate post-translationally modified islet autoantigens.

McLaughlin RJ, de Haan A, Zaldumbide A, de Koning EJ, de Ru AH, van Veelen PA, van Lummel M, Roep BO.

Clin Exp Immunol. 2016 Aug;185(2):133-40. doi: 10.1111/cei.12775. Epub 2016 May 17.

18.

Discovery of a Selective Islet Peptidome Presented by the Highest-Risk HLA-DQ8trans Molecule.

van Lummel M, van Veelen PA, de Ru AH, Pool J, Nikolic T, Laban S, Joosten A, Drijfhout JW, Gómez-Touriño I, Arif S, Aanstoot HJ, Peakman M, Roep BO.

Diabetes. 2016 Mar;65(3):732-41. doi: 10.2337/db15-1031. Epub 2015 Dec 30.

19.

Proteasomal Degradation of Proinsulin Requires Derlin-2, HRD1 and p97.

Hoelen H, Zaldumbide A, van Leeuwen WF, Torfs EC, Engelse MA, Hassan C, Lebbink RJ, de Koning EJ, Resssing ME, de Ru AH, van Veelen PA, Hoeben RC, Roep BO, Wiertz EJ.

PLoS One. 2015 Jun 24;10(6):e0128206. doi: 10.1371/journal.pone.0128206. eCollection 2015.

20.

ICL-induced miR139-3p and miR199a-3p have opposite roles in hematopoietic cell expansion and leukemic transformation.

Alemdehy MF, Haanstra JR, de Looper HW, van Strien PM, Verhagen-Oldenampsen J, Caljouw Y, Sanders MA, Hoogenboezem R, de Ru AH, Janssen GM, Smetsers SE, Bierings MB, van Veelen PA, von Lindern M, Touw IP, Erkeland SJ.

Blood. 2015 Jun 18;125(25):3937-48. doi: 10.1182/blood-2014-11-612507. Epub 2015 Mar 16.

PMID:
25778535
21.

Temporal SILAC-based quantitative proteomics identifies host factors involved in chikungunya virus replication.

Treffers EE, Tas A, Scholte FE, Van MN, Heemskerk MT, de Ru AH, Snijder EJ, van Hemert MJ, van Veelen PA.

Proteomics. 2015 Jul;15(13):2267-80. doi: 10.1002/pmic.201400581. Epub 2015 Apr 22.

PMID:
25764339
22.

Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte-Derived HLA-Ligandome Using a Reverse Immunology Approach.

Hombrink P, Hassan C, Kester MG, Jahn L, Pont MJ, de Ru AH, van Bergen CA, Griffioen M, Falkenburg JH, van Veelen PA, Heemskerk MH.

Clin Cancer Res. 2015 May 1;21(9):2177-86. doi: 10.1158/1078-0432.CCR-14-2188. Epub 2015 Jan 14.

23.

Comprehensive analysis of the mouse brain proteome sampled in mass spectrometry imaging.

Heijs B, Carreira RJ, Tolner EA, de Ru AH, van den Maagdenberg AM, van Veelen PA, McDonnell LA.

Anal Chem. 2015 Feb 3;87(3):1867-75. doi: 10.1021/ac503952q. Epub 2015 Jan 13.

PMID:
25535922
24.

Naturally processed non-canonical HLA-A*02:01 presented peptides.

Hassan C, Chabrol E, Jahn L, Kester MG, de Ru AH, Drijfhout JW, Rossjohn J, Falkenburg JH, Heemskerk MH, Gras S, van Veelen PA.

J Biol Chem. 2015 Jan 30;290(5):2593-603. doi: 10.1074/jbc.M114.607028. Epub 2014 Dec 12.

25.

Identification and characterisation of peptide binding motifs of six autoimmune disease-associated human leukocyte antigen-class I molecules including HLA-B*39:06.

Eichmann M, de Ru A, van Veelen PA, Peakman M, Kronenberg-Versteeg D.

Tissue Antigens. 2014 Oct;84(4):378-88. doi: 10.1111/tan.12413. Epub 2014 Aug 25.

PMID:
25154780
26.

Accurate quantitation of MHC-bound peptides by application of isotopically labeled peptide MHC complexes.

Hassan C, Kester MG, Oudgenoeg G, de Ru AH, Janssen GM, Drijfhout JW, Spaapen RM, Jiménez CR, Heemskerk MH, Falkenburg JH, van Veelen PA.

J Proteomics. 2014 Sep 23;109:240-4. doi: 10.1016/j.jprot.2014.07.009. Epub 2014 Jul 19.

PMID:
25050860
27.

Disclosure of selective advantages in the "modern" sublineage of the Mycobacterium tuberculosis Beijing genotype family by quantitative proteomics.

de Keijzer J, de Haas PE, de Ru AH, van Veelen PA, van Soolingen D.

Mol Cell Proteomics. 2014 Oct;13(10):2632-45. doi: 10.1074/mcp.M114.038380. Epub 2014 Jul 14.

28.

Voluntary contraction of the tensor tympani muscle and its audiometric effects.

De Ru A, Heerens W, Packer M.

J Laryngol Otol. 2014 Mar 19:1. [Epub ahead of print] No abstract available.

PMID:
24641792
29.

The human peptidylarginine deiminases type 2 and type 4 have distinct substrate specificities.

Assohou-Luty C, Raijmakers R, Benckhuijsen WE, Stammen-Vogelzangs J, de Ru A, van Veelen PA, Franken KL, Drijfhout JW, Pruijn GJ.

Biochim Biophys Acta. 2014 Apr;1844(4):829-36. doi: 10.1016/j.bbapap.2014.02.019. Epub 2014 Mar 2.

PMID:
24594197
30.

Posttranslational modification of HLA-DQ binding islet autoantigens in type 1 diabetes.

van Lummel M, Duinkerken G, van Veelen PA, de Ru A, Cordfunke R, Zaldumbide A, Gomez-Touriño I, Arif S, Peakman M, Drijfhout JW, Roep BO.

Diabetes. 2014 Jan;63(1):237-47. doi: 10.2337/db12-1214. Epub 2013 Oct 2.

31.

Unique peptide-binding motif for Mamu-B*037:01: an MHC class I allele common to Indian and Chinese rhesus macaques.

de Groot NG, Heijmans CM, de Ru AH, Hassan C, Otting N, Doxiadis GG, Koning F, van Veelen PA, Bontrop RE.

Immunogenetics. 2013 Dec;65(12):897-900. doi: 10.1007/s00251-013-0734-5. Epub 2013 Sep 17.

PMID:
24042460
32.

The human leukocyte antigen-presented ligandome of B lymphocytes.

Hassan C, Kester MG, de Ru AH, Hombrink P, Drijfhout JW, Nijveen H, Leunissen JA, Heemskerk MH, Falkenburg JH, van Veelen PA.

Mol Cell Proteomics. 2013 Jul;12(7):1829-43. doi: 10.1074/mcp.M112.024810. Epub 2013 Mar 12.

33.

Discovery of T cell epitopes implementing HLA-peptidomics into a reverse immunology approach.

Hombrink P, Hassan C, Kester MG, de Ru AH, van Bergen CA, Nijveen H, Drijfhout JW, Falkenburg JH, Heemskerk MH, van Veelen PA.

J Immunol. 2013 Apr 15;190(8):3869-77. doi: 10.4049/jimmunol.1202351. Epub 2013 Mar 8.

34.

Efficient -2 frameshifting by mammalian ribosomes to synthesize an additional arterivirus protein.

Fang Y, Treffers EE, Li Y, Tas A, Sun Z, van der Meer Y, de Ru AH, van Veelen PA, Atkins JF, Snijder EJ, Firth AE.

Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):E2920-8. doi: 10.1073/pnas.1211145109. Epub 2012 Oct 4.

35.

Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2.

Lampen MH, Hassan C, Sluijter M, Geluk A, Dijkman K, Tjon JM, de Ru AH, van der Burg SH, van Veelen PA, van Hall T.

Mol Immunol. 2013 Jan;53(1-2):126-31. doi: 10.1016/j.molimm.2012.07.009. Epub 2012 Aug 13.

PMID:
22898188
36.

Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells.

van Luijn MM, van de Loosdrecht AA, Lampen MH, van Veelen PA, Zevenbergen A, Kester MG, de Ru AH, Ossenkoppele GJ, van Hall T, van Ham SM.

PLoS One. 2012;7(4):e34649. doi: 10.1371/journal.pone.0034649. Epub 2012 Apr 26.

37.

Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill β-cells.

Kronenberg D, Knight RR, Estorninho M, Ellis RJ, Kester MG, de Ru A, Eichmann M, Huang GC, Powrie J, Dayan CM, Skowera A, van Veelen PA, Peakman M.

Diabetes. 2012 Jul;61(7):1752-9. doi: 10.2337/db11-1520. Epub 2012 Apr 20.

38.

Efficiency and mechanism of antigen-specific CD8+ T-cell activation using synthetic long peptides.

Zandvliet ML, Kester MG, van Liempt E, de Ru AH, van Veelen PA, Griffioen M, Guchelaar HJ, Falkenburg JH, Meij P.

J Immunother. 2012 Feb-Mar;35(2):142-53. doi: 10.1097/CJI.0b013e318243f1ed.

PMID:
22306902
39.

Type 1 diabetes-associated HLA-DQ8 transdimer accommodates a unique peptide repertoire.

van Lummel M, van Veelen PA, Zaldumbide A, de Ru A, Janssen GM, Moustakas AK, Papadopoulos GK, Drijfhout JW, Roep BO, Koning F.

J Biol Chem. 2012 Mar 16;287(12):9514-24. doi: 10.1074/jbc.M111.313940. Epub 2011 Dec 19.

40.

Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific.

Amir AL, van der Steen DM, Hagedoorn RS, Kester MG, van Bergen CA, Drijfhout JW, de Ru AH, Falkenburg JH, van Veelen PA, Heemskerk MH.

Blood. 2011 Dec 22;118(26):6733-42. doi: 10.1182/blood-2011-05-354787. Epub 2011 Oct 4.

PMID:
21972290
41.

PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer.

Amir AL, van der Steen DM, van Loenen MM, Hagedoorn RS, de Boer R, Kester MD, de Ru AH, Lugthart GJ, van Kooten C, Hiemstra PS, Jedema I, Griffioen M, van Veelen PA, Falkenburg JH, Heemskerk MH.

Clin Cancer Res. 2011 Sep 1;17(17):5615-25. doi: 10.1158/1078-0432.CCR-11-1066. Epub 2011 Jul 19.

42.

MiR-17/20/93/106 promote hematopoietic cell expansion by targeting sequestosome 1-regulated pathways in mice.

Meenhuis A, van Veelen PA, de Looper H, van Boxtel N, van den Berge IJ, Sun SM, Taskesen E, Stern P, de Ru AH, van Adrichem AJ, Demmers J, Jongen-Lavrencic M, Löwenberg B, Touw IP, Sharp PA, Erkeland SJ.

Blood. 2011 Jul 28;118(4):916-25. doi: 10.1182/blood-2011-02-336487. Epub 2011 May 31.

43.

Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes.

Kessler JH, Khan S, Seifert U, Le Gall S, Chow KM, Paschen A, Bres-Vloemans SA, de Ru A, van Montfoort N, Franken KL, Benckhuijsen WE, Brooks JM, van Hall T, Ray K, Mulder A, Doxiadis II, van Swieten PF, Overkleeft HS, Prat A, Tomkinson B, Neefjes J, Kloetzel PM, Rodgers DW, Hersh LB, Drijfhout JW, van Veelen PA, Ossendorp F, Melief CJ.

Nat Immunol. 2011 Jan;12(1):45-53. doi: 10.1038/ni.1974. Epub 2010 Dec 12.

PMID:
21151101
44.

HSPVdb--the Human Short Peptide Variation Database for improved mass spectrometry-based detection of polymorphic HLA-ligands.

Nijveen H, Kester MG, Hassan C, Viars A, de Ru AH, de Jager M, Falkenburg JH, Leunissen JA, van Veelen PA.

Immunogenetics. 2011 Mar;63(3):143-53. doi: 10.1007/s00251-010-0497-1. Epub 2010 Dec 2.

45.

Development of an activity-based probe for autotaxin.

Cavalli S, Houben AJ, Albers HM, van Tilburg EW, de Ru A, Aoki J, van Veelen P, Moolenaar WH, Ovaa H.

Chembiochem. 2010 Nov 2;11(16):2311-7. doi: 10.1002/cbic.201000349.

PMID:
20941725
46.

Activity-based profiling reveals reactivity of the murine thymoproteasome-specific subunit beta5t.

Florea BI, Verdoes M, Li N, van der Linden WA, Geurink PP, van den Elst H, Hofmann T, de Ru A, van Veelen PA, Tanaka K, Sasaki K, Murata S, den Dulk H, Brouwer J, Ossendorp FA, Kisselev AF, Overkleeft HS.

Chem Biol. 2010 Aug 27;17(8):795-801. doi: 10.1016/j.chembiol.2010.05.027.

47.

AIDS-protective HLA-B*27/B*57 and chimpanzee MHC class I molecules target analogous conserved areas of HIV-1/SIVcpz.

de Groot NG, Heijmans CM, Zoet YM, de Ru AH, Verreck FA, van Veelen PA, Drijfhout JW, Doxiadis GG, Remarque EJ, Doxiadis II, van Rood JJ, Koning F, Bontrop RE.

Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15175-80. doi: 10.1073/pnas.1009136107. Epub 2010 Aug 9.

48.

The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects.

Oliveira CC, van Veelen PA, Querido B, de Ru A, Sluijter M, Laban S, Drijfhout JW, van der Burg SH, Offringa R, van Hall T.

J Exp Med. 2010 Jan 18;207(1):207-21. doi: 10.1084/jem.20091429. Epub 2009 Dec 28. Erratum in: J Exp Med. 2010 Mar 15;207(3):671. Drijfhout, Jan W [added].

49.

Fine specificity of monoclonal antibodies against celiac disease-inducing peptides in the gluteome.

Mitea C, Kooy-Winkelaar Y, van Veelen P, de Ru A, Drijfhout JW, Koning F, Dekking L.

Am J Clin Nutr. 2008 Oct;88(4):1057-66.

PMID:
18842794
50.

Dominance of an alternative CLIP sequence in the celiac disease associated HLA-DQ2 molecule.

Wiesner M, Stepniak D, de Ru AH, Moustakis AK, Drijfhout JW, Papadopoulos GK, van Veelen PA, Koning F.

Immunogenetics. 2008 Sep;60(9):551-5. doi: 10.1007/s00251-008-0310-6. Epub 2008 Jun 27.

Supplemental Content

Support Center